US FDA completes surveillance inspection of Cohance Life Sciences' API plant at Nacharam Facility.

Received form 483 with 4 observations.

Hyderabad, March 07, 2025

The United States Food and Drug Administration (US FDA) completed a surveillance inspection of Cohance Lifesciences' API Unit-IV, located in Nacharam, Hyderabad from March 3, 2025 to March 7, 2025.

Following the inspection, the facility received a Form 483 with four observations, which are largely procedural in nature.

The Cohance team is committed to addressing these observations within the stipulated timeline.

The proposed amalgamation of Suven Pharmaceuticals and Cohance Life Sciences is currently in process and awaiting necessary approvals, (awaiting NCLT and any other required approvals).

-ENDS-

For more information, please contact:

Cyndrella Carvalho, Head - Investor Relations,
Suven Pharmaceutical Ltd
Tel: 040 2354 3311
Email: cyndrella.carvalho@suvenpharm.com

Gavin Desa / Rishab Barar
CDR India
Tel: +91 98206 37649/ +91 77770 35061
Email: gavin@cdr-india.com
rishab@cdr-india.com